Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applying cognitive interviewing process to refine an instrument for measuring deprescribing experience and outcomes in older veterans.

Journal of patient-reported outcomes·2026
Same author

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Unraveling the dynamics of organic phosphorus and its role in internal phosphorus feedback during algal blooms senescence.

Water research·2026
Same author

A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

MEMS-based large-field-of-view optical coherence tomography endoscopy for gastric ulcer imaging in mice.

Biomedical optics express·2026
Same author

Methodological Reflections from Engaging Five Culturally and Linguistically Unique U.S. Muslim Populations.

Healthcare (Basel, Switzerland)·2026

Related Experiment Videos

Racial difference in diabetes preventive care.

Jia Pu1, Betty Chewning

  • 1School of Pharmacy, University of Wisconsin-Madison, Wisconsin, United States.

Research in Social & Administrative Pharmacy : RSAP
|December 19, 2012
PubMed
Summary

Racial disparities persist in diabetes preventive care, with minority, rural, and low-income individuals being less likely to receive essential screenings. Pharmacists can play a key role in addressing these gaps.

Keywords:
Andersen's Health Care Utilization Behavior modelDiabetes preventive careRacial difference

Related Experiment Videos

Area of Science:

  • Health Services Research
  • Health Disparities
  • Preventive Medicine

Background:

  • Diabetes is a leading cause of death globally, necessitating preventive services to mitigate complications.
  • Racial disparities in receiving diabetes preventive care are documented, but contributing factors remain unclear.

Purpose of the Study:

  • To identify mediators linking race/ethnic disparities to reduced receipt of diabetes preventive care.
  • To understand the dynamics between race/ethnicity and preventive care access.
  • To explore the role of pharmacists in addressing these disparities.

Main Methods:

  • Utilized 2008 Medical Expenditure Panel Survey (MEPS) data for the U.S. non-institutionalized population.
  • Employed logistic regression and path analysis to examine direct and indirect effects of race/ethnicity on preventive care receipt.
  • Identified household income and health insurance as potential mediators based on Andersen's Health Care Utilization Behavior model.

Main Results:

  • Racial differences were observed in A1C tests, diabetic foot exams, and eye exams, persisting after controlling for demographic and socioeconomic factors.
  • Hispanics were least likely to receive all three preventive care elements.
  • Younger age, rural living, lower income, and lack of insurance were associated with reduced preventive care; lower income and lack of insurance partially explained disparities in minority patients.

Conclusions:

  • Minority, rural, low-income, uninsured, and young individuals with diabetes are at higher risk for inadequate preventive care.
  • Path analysis revealed significant racial disparities in diabetes preventive care, mediated by socioeconomic factors.
  • Pharmacists are positioned to identify and address gaps in diabetes preventive care through patient assessment, education, and monitoring.